LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has granted marketing authorisation for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol, ‘FF/UMEC/VI') as a maintenance
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that management will present at the following healthcare-focused investment banking conferences in November 2017 : Credit Suisse 26th Annual Healthcare Conference November 8, 2017 at 12:20 pm MT Scottsdale, Arizona
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive data from a study comparing a once-daily long-acting muscarinic antagonist (LAMA) and a long-acting beta agonist (LABA) fixed-dose combination, Anoro Ellipta
Royalties earned in the third quarter of 2017 of $51.9 million , up 42% from the third quarter of 2016. Completed the full refinancing of the 9% non-recourse term notes due 2029. Plans to repurchase up to $80 million of common stock, pursuant to an accelerated share repurchase (ASR) plan, which
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the third quarter ended September 30, 2017 after market close on Wednesday, October 25, 2017 . Following the earnings release, Innoviva management will host a webcast and
BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) today announced that Michael W. Aguiar, Innoviva's President and Chief Executive Officer and Eric d'Esparbes, SVP and Chief Financial Officer will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September
Trelegy Ellipta met study primary endpoint demonstrating reduction in exacerbations compared with the dual therapies Anoro Ellipta and Relvar/Breo Ellipta in patients with COPD LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc.
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration (FDA) has approved once-daily, single inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI), under the brand name
LONDON --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending marketing authorisation for fluticasone
Relvar Ellipta was superior to usual care treatment in improving asthma control for patients in Salford Lung Study. LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced positive results from the Salford Lung Study